Результаты поиска

Effectiveness of a digital medication event reminder and monitor device for patients with tuberculosis (SELFTB): a multicenter randomized controlled trial.

BACKGROUND: Tuberculosis remains the leading cause of death from a single infectious disease worldwide. Trials evaluating digital adherence … is [57 control and 57 intervention participants]. Participants were 64.9% male, 15% with HIV, 10.5% retreatment, and 5.3% homeless. Adherence to TB medication was comparable between the intervention arm [geometric mean percentage (GM%) 99.01%, geometric standard deviation (GSD) 1.02] and the control arm [GM% 98.97%, GSD 1.04] and was within the prespecified m …

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

OBJECTIVES: To assess the clinical-effectiveness and cost-effectiveness of pegylated interferon-alpha combined with ribavirin in the treatme … further research is needed. These include: efficacies of therapy with PEG-alpha-2a vs PEG-alpha-2b; retreatment of previous non-responders using pegylated interferon; efficacy of treatments and long-term outcomes in patients who have other co-morbidities; prospective tests of rules governing stopping treatment; treating patients with acute hepatitis C; proble …

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

PURPOSE: To determine if photodynamic therapy with verteporfin (Visudyne; Novartis AG, Bülach, Switzerland), termed verteporfin therapy, can … of the choroidal neovascularization lesion on the retina. At follow-up examinations every 3 months, retreatment with the same regimen was applied if angiography showed fluorescein leakage. The main outcome measure was at least moderate vision loss, that is, a loss of at least 15 letters (approximately 3 lines), adhering to an intent-to-treat analysis with the …

The burden of major adverse cardiac events in patients with coronary artery disease.

BACKGROUND: Patients with a history of cardiovascular disease are at high risk of developing secondary major adverse cardiac events (MACE). This study aimed to identify independent predictors of MACE after hospital admission which could be used to identify of high-risk patients who may benefit from preventive strategies. METHODS: This study included 1,520 consecutive patients with coronary artery disease (CAD) (654 with acute coronary syndrome (ACS) and 866 with elective percutaneous coronary intervention (PCI) patients) who received PCI and/or stenting. MACE was defined as all-cause mortalit

The unnatural history of pulmonary stenosis up to 40 years after surgical repair.

OBJECTIVE: To provide prospective information on long-term outcome after surgical correction of valvular pulmonary stenosis (PS). METHODS: Fifty-three consecutive patients operated for PS during childhood between 1968 and 1980 in one centre are followed longitudinally for 37±3.4 years, including extensive in-hospital examination every 10 years. RESULTS: Survival information was available in 100% of the original 53 patients. Cumulative survival was 94% at 20 years and 91% at 40 years. Excluding perioperative mortality (<30 days), survival was 94% at 40 years. Of 46 eligible survivors, 29 part

Statement of the Independent Forensic Expert Group on Conversion Therapy.

Conversion therapy is a set of practices that aim to change or alter an individual's sexual orientation or gender identity. It is premised on a belief that an individual's sexual orientation or gender identity can be changed and that doing so is a desirable outcome for the individual, family, or community. Other terms used to describe this practice include sexual orientation change effort (SOCE), reparative therapy, reintegrative therapy, reorientation therapy, ex-gay therapy, and gay cure. Conversion therapy is practiced in every region of the world. We have identified sources confirming or i

Diagnosis and treatment of Paget's disease of bone: position paper from the Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS).

INTRODUCTION: Paget's disease of bone is a focal skeletal disorder causing bone deformities and impairing bone quality. Despite the prevalence of asymptomatic cases is increasing, the progression of the disease can lead to invalidating complications that compromise the quality of life. Doubts on clinical and therapeutic management aspects exist, although beneficial effects of antiresorptive drugs, particularly bisphosphonates are known. However, limited information is available from randomized controlled trials on the prevention of disease complications so that somewhat contrasting positions a

Совпадение в полном тексте источника
… In case of recurrence of disease activity during the follow-up (e.g., increased t-ALP levels), especially in the presence of painful symptoms, a decision about a possible retreatment is mandatory [ 2 , 16 ] (see “ Is antiresorptive retreatment indicated in a patient previously ” for more details). … Of interest, all but one patient reported a decrease in bone pain after retreatment. …

Botulinum toxin for the treatment of strabismus.

BACKGROUND: The use of botulinum toxin as an investigative and treatment modality for strabismus is well reported in the medical literature. … nce). Two studies conducted in Spain compared botulinum toxin with surgery in children who required retreatment for acquired or infantile esotropia. These two studies provided low-certainty evidence that botulinum toxin may have little to no effect on achieving sensory fusion (RR 0.88, 95% CI 0.63 to 1.23; I² = 0%; 2 studies, 102 participants) and stereopsis …

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

BACKGROUND: Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EG … tients received durvalumab (10 mg/kg) every 2 weeks, via intravenous infusion, for up to 12 months. Retreatment was allowed for patients who benefited but then progressed after completing 12 months. The primary endpoint was the proportion of patients with increased tumour expression of PD-L1 (defined as ≥25% of tumour cells in cohorts 1 and 2, and ≥90% of tum …

Экономичность atumumumab для лечения повторной формы множественных склерозов в Объединенных Арабских Эмиратах.

Множественный склероз (MS) — аутоиммунное заболевание центральной нервной системы, связанное с обезвоживанием и воспалением. Повторные формы MS (RMS) охватывают всех пациентов, у которых MS испытывает рецидивы. Несмотря на то, что в настоящее время не существует лекарств для лечения MS, внедрение нескольких методов лечения, позволяющих регулировать заболевания (DMT), значительно уменьшило риск рецидива и инвалидности у пациентов с MS. Существует острая потребность в легком для использования DMT, который можно использовать на раннем этапе лечения.ЦЕЛИ: Данное исследование было направлено на оце

Совпадение в полном тексте источника
… The base-case analysis assumed cladribine tablets were administered in two cycles, separated by 12 months, with no further retreatment. A scenario analysis explored the impact of retreatment with cladribine beyond Year 4. … However, given the lack of data on the frequency of retreatment with cladribine, any such comparisons are likely to be considered speculative. …

Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model.

IntroductionThe COVID-19 pandemic has challenged healthcare systems worldwide over the last few months, and it continues to do so. Although some restrictions are being removed, it is not certain when the pandemic is going to be definitively over. Pandemics can be seen as a highly complex logistic scenario. From this perspective, some of the indications provided for palliative radiotherapy (PRT) during the COVID-19 pandemic could be maintained in the future in settings that limit the possibility of patients achieving symptom relief by radiotherapy. This paper has two aims: (1) to provide a summ

Совпадение в полном тексте источника
… QP4b AIRO Pall 8 Gy/1fx8Gy SBRT Single fraction (16 to 24 Gy) SBRT for Retreatment of Symptomatic MESCC • Waiting a minimum of 6 weeks after completion of the initial RT A = 92% [SA = 42%] D = 8% [SD = 0%] • For highly selected clinical settings of extensive bone involvement, or retreatment/ pain refractory … QP4b | AIRO Pall | 8 Gy/1fx8Gy | SBRT Single fraction (16 to 24 Gy) SBRT for Retreatment of Symptomatic MESCC | • Waiting a minimum of 6 weeks after completion of the initial RT | A = 92% [SA = 42%] | D = 8% [SD = 0%] • For highly selected clinical settings of extensive bone involvement, or retreatment …

Использование кладрибина в повторном склерозе после 8-10 лет: два сообщения о пациентах из исследования ORACLE-MS.

Cladribine — иммунная реконструктивная терапия для многократного склероза (MS), которая избирательно приводит к долгосрочному сокращению высокопатологической памяти клеток B с временным сокращением других подгрупп B- и T-клеток, тем самым восстанавливая иммунную функцию ближе к базовым уровням в краткосрочной перспективе. Здесь мы описываем два случая повторного использования MS (RMS), обработанных вторым курсом кладрибина. Первоначально у обоих пациентов был диагностирован клинически изолированный синдром, а позднее они были охвачены исследованиями ОРАКЛЕ-МС и CLASSIC-MS. После получения клад

Совпадение в полном тексте источника
… Both patients subsequently entered the CLASSIC-MS study and experienced disease stability for 8-10 years until MS was retreated with a second course of cladribine, the outcomes of which are described here. … Both were then retreated with a second course of cladribine for RMS, thus highlighting not only the long-term efficacy of the drug but also that retreatment is well tolerated. …

Decision Making in Patients With Metastatic Spine. The Role of Minimally Invasive Treatment Modalities.

Spine metastases affect more than 70% of terminal cancer patients that eventually suffer from severe pain and neurological symptoms. Nevertheless, in the overwhelming majority of the cases, a spinal metastasis represents just one location of a diffuse systemic disease. Therefore, the best practice for treatment of spinal metastases depends on many different aspects of an oncological disease, including the assessment of neurological status, pain, location, and dissemination of the disease as well as the ability to predict the risk of disease progression with neurological worsening, benefits and

Совпадение в полном тексте источника
… An important RCT evaluated re-irradiation doses of 20 Gy in 5 fractions and 8 Gy in 1 fraction using EBRT techniques for painful bony metastases requiring retreatment ( 74 ). … The first issue of reirradiation is dose that can be used to retreat the spine. …

From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.

The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time-limited, targeted regimens. High-sensitivity MRD assessment, enabled by multicolor flow cytometry, allele-specific oligonucleotide PCR, and next-generation sequencing (NGS), provides a robust, quantifiable measure for depth of remission and long-term outcomes. Landmark trials-including CLL14, MURANO, CAPTIVATE, and GLOW-have consistently demonstrated that achieving undetectable

Совпадение в полном тексте источника
… This early‐warning capability is particularly relevant for patients undergoing time‐limited therapy, where the timing of MRD reappearance can guide retreatment and prolong remission within the framework of clinical trials and carefully designed monitoring protocols. … J., et al., “The MURANO Study: Final Analysis and Retreatment/Crossover Substudy Results of VenR for Patients With Relapsed/Refractory CLL,” Blood 145, no. 23 (2025): 2733–2745. 54. Mauro F. R., Starza I. …

Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding.

BACKGROUND: Heavy menstrual bleeding (HMB), which includes both menorrhagia and metrorrhagia, is an important cause of ill health in women. … tial cost of endometrial destruction is significantly lower than that of hysterectomy, but, because retreatment is often necessary, the cost difference narrows over time.

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.

Ixazomib is an investigational proteasome inhibitor that has shown preclinical activity in lymphoma models. This phase 1 study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics and preliminary activity of intravenous (IV) ixazomib in relapsed/refractory lymphoma patients who had received ⩾ 2 prior therapies. Thirty patients with a range of histologies received ixazomib 0.125-3.11 mg/m(2) on days 1, 8 and 15 of 28-day cycles. Patients received a median of two cycles (range 1-36). MTD was determined to be 2.34 mg/m(2). Most common drug-related ad

Совпадение в полном тексте источника
… At the time of reporting, the patient had received 18 retreatment cycles and had a PR at the last scan at retreatment cycle 8. The treatment histories of the five responding patients are shown in Table 5 . … Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol. 2009;84:657–660. doi: 10.1002/ajh.21517. …

Последовательность BCMA- и GPRC5D-targeting Иммунотерапия в множестве миеломы: практическое руководство Европейской сети миеломы.

В последние годы с появлением нового BCMA- и GPRC5D-directed Иммунотерапия, включая терапию ЦАР-Т-клеток, биконкретные антитела (BSAbs) и антитела-наркотики (ADC). Выбор и последовательность лечения становятся все более сложными с учетом широкого круга вариантов лечения. В этом обзоре Европейская сеть &lt; &lt; Миэлома &gt; &gt; дает рекомендации о том, как лучше всего включить эти новые методы лечения в нынешнюю систему лечения с использованием имеющихся данных. Оптимальная последовательность лечения зависит от различных особенностей, связанных с пациентом и опухолью, а также от компенсации и

Совпадение в полном тексте источника
… In the KarMMa study, 28 patients were retreated with ide‐cel at the time of progression. … retreatment was associated with limited anti‐MM efficacy and CAR T‐cell expansion. 60 Furthermore, retreatment at the time of progression was also largely ineffective with FCARH143, a fully human BCMA‐directed CAR T‐cell product. 44 Sequential cellular BCMA‐directed therapy: Different CAR T‐cell product …

Management of Long Bones Metastatic Disease: Concepts That We All Know but Not Always Remember.

Bones are the third most common site of metastatic disease. Treatment is rarely curative; rather, it seeks to control disease progression and palliate symptoms. Imaging evaluation of a patient with symptoms of metastatic bone disease should begin with plain X-rays. Further imaging consists of a combination of (PET)-CT scan and bone scintigraphy. We recommend performing a biopsy after imaging workup has been conducted. Metastatic bone disease is managed with a combination of systemic treatment, radiotherapy (RT), and surgery. External beam RT (EBRT) is used for pain control and postoperatively

Совпадение в полном тексте источника
… EBRT. 24 Van der Linden et al retrospectively reviewed data from the Dutch Bone Metastasis Study and found that with or without the effect of retreatment, SF and MF radiotherapy provided equal palliation for painful bone metastasis. 23 These results show that physicians are more likely to retreat patients … Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment . Int J Radiat Oncol Biol Phys . 2004 ; 59 ( 2 ): 528 – 537 . doi: 10.1016/j.ijrobp.2003.10.006 15145173 24. Lutz S , Balboni T , Jones J , et al. …

Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma.

Triple-class-refractory multiple myeloma (MM) describes MM refractory to proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies. In the Phase IIb STORM study (NCT02336815), oral selinexor plus low-dose dexamethasone (Sel-dex) demonstrated a 26.2% overall response rate in triple-class-refractory MM. Here, we compare overall survival (OS) of 122 patients with triple-class-refractory MM who received Sel-dex in STORM Part 2 with that of 64 similar patients treated with other available therapies in a Flatiron Health Analytic Database (FHAD) cohort. OS from the date that

Совпадение в полном тексте источника
… Retreatment/recycling with PI and IMiD therapies was chosen most frequently for subsequent treatment, either as monotherapy or as part of a combination regimen. … In this context, the key finding in this analysis was that the median OS with Sel‐dex in the STORM cohort was nearly double that compared to retreatment approaches used in the FHAD cohort. …

Harnessing the Immune System: Current and Emerging Immunotherapy Strategies for Pediatric Acute Lymphoblastic Leukemia.

Treatment for relapsed acute lymphoblastic leukemia (ALL) in children and young adults continues to evolve. Despite optimization of cytotoxic chemotherapeutic approaches and risk-adapted therapy, about 12% of pediatric patients still relapse, and survival rates in this population remain poor. Salvage therapy for relapsed patients continues to be challenging as attempts to further intensify chemotherapy have resulted in excessive toxicity without improving outcomes. Immunotherapy has profoundly impacted the landscape of relapsed ALL by harnessing the patient's immune system to target and elimin

Совпадение в полном тексте источника
… cohort: 1 patient proceeded to HSCT due to early B-cell recovery | 6 mo cumulative incidence of loss of CAR-T persistence: 27% (CAR-naïve) and 48% (retreatment cohort) | CAR-naïve: CRS: 90% (any grade), 15% (grade ≥ 3) ICANS: 41% (any grade), 7% (grade ≥ 3) Retreatment cohort: CRS: 76% (any grade), … a CR rate of 64% in the retreatment cohort, 86% of whom were MRD-negative. …